Suven Life Sciences is currently trading at Rs. 256.00, up by 3.45 points or 1.37% from its previous closing of Rs. 252.55 on the BSE.
The scrip opened at Rs. 252.00 and has touched a high and low of Rs. 259.00 and Rs. 250.10 respectively. So far 86201 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 174.75 on 07-Oct-2014.
Last one week high and low of the scrip stood at Rs. 268.00 and Rs. 238.00 respectively. The current market cap of the company is Rs. 3257.80 crore.
The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 7.49% and 33.06% respectively.
Suven Life Sciences has bagged Pharmexcil’s ‘Gold Patent Award’ for securing the most number of product patents under NCE category. The Awards were presented during the ‘Awards Function for Exports and patents during 11th Annual General Meet of Pharmexcil at Hyderabad’.
The company has secured 77 product patents for their NCE’s during 2014-2015 from several countries including all the developed countries like USA, Europe, Japan, Australia and Canada etc. So far the company has secured a total of 753 product patents globally for their NCE’s and 37 process patents.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: